KNSA
Kiniksa Pharmaceuticals, Ltd.
NASDAQ · BMHealthcareBiotechnology
$62.58-2.14%
Price as of Jul 20, 2026
KNSA profitability
Kiniksa Pharmaceuticals, Ltd. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 54.6%
- EBITDA margin
- 14.3%
- EBIT margin
- 12.4%
- Net margin
- 9.7%
- Free cash flow margin
- 21.8%
Returns
- Return on equity
- 12.1%
- Return on assets
- 8.9%
- Return on invested capital
- 15.2%
- Asset turnover
- 0.95x
Cash efficiency
- Cash from operations
- $165.9M
- Cash per share
- $6.08
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.